Long-term treatment with oral N-acetylcysteine: Affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial

Journal of Cystic Fibrosis

Volumn 14, Issue 2, 2015, Pages 219-227

  Conrad, C ^a   Lymp, J ^c   Thompson, V ^c   Dunn, C ^a   Davies, Z ^a   Chatfield, B ^d   Nichols, D ^e   Clancy, J ^f   Vender, R ^g   Egan, M E ^h   Quittell, L ⁱ   Michelson, P ^j   Antony, V ^k   Spahr, J ^l   Rubenstein, R C ^m   Moss, R B ^a   Herzenberg, L A ⁿ   Goss, C H ^c   Tirouvanziam, R ^b  

^a STANFORD UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CFFT Therapeutics Development Network Coordinating Center   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e DEPARTMENT OF MEDICINE   (United States)

^f CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^g PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^h YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ NewYork Presbyterian Hospital   (United States)

^j ST LOUIS CHILDREN S HOSPITAL   (United States)

^k UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^l CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^m CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

ⁿ STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Anti oxidant; Clinical trial; Cystic fibrosis; Glutathione; Lung function

Indexed keywords

ACETYLCYSTEINE; ANTIBIOTIC AGENT; GLUTATHIONE; INTERLEUKIN 8; LEUKOCYTE ELASTASE; PLACEBO; ANTIOXIDANT;

ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CYSTIC FIBROSIS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FORCED EXPIRATORY VOLUME; HUMAN; INFLAMMATION; LONG TERM CARE; LUNG DIFFUSION CAPACITY; LUNG FIBROSIS; LUNG FUNCTION; MULTICENTER STUDY; NEUTROPHIL COUNT; PHASE 2 CLINICAL TRIAL; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; SPUTUM; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; DRUG MONITORING; FEMALE; LUNG; LUNG FUNCTION TEST; MALE; METABOLISM; ORAL DRUG ADMINISTRATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROCEDURES; TIME; TREATMENT OUTCOME;

ACETYLCYSTEINE; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIOXIDANTS; CHILD; CYSTIC FIBROSIS; DOUBLE-BLIND METHOD; DRUG MONITORING; FEMALE; HUMANS; INFLAMMATION; LEUKOCYTE ELASTASE; LUNG; MALE; OXIDATIVE STRESS; RESPIRATORY FUNCTION TESTS; SPUTUM; TIME; TREATMENT OUTCOME;

EID: 84924340525     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2014.08.008     Document Type: Article

References (36)

1. Roum J.H., Buhl R., McElvaney N.G., Borok Z., Crystal R.G. Systemic deficiency of glutathione in cystic fibrosis. J Appl Physiol Dec 1993, 75(6):2419-2424. [PubMed PMID: 8125859. Epub 1993/12/01. eng].
2. Konstan M.W., Hilliard K.A., Norvell T.M., Berger M. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med Aug 1994, 150(2):448-454. [PubMed PMID: 8049828. Epub 1994/08/01. eng].
3. Khan T.Z., Wagener J.S., Bost T., Martinez J., Accurso F.J., Riches D.W. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med Apr 1995, 151(4):1075-1082. [PubMed PMID: 7697234. Epub 1995/04/01. eng].
4. Armstrong D.S., Grimwood K., Carlin J.B., Carzino R., Gutierrez J.P., Hull J., et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med Oct 1997, 56(4 Pt 1):1197-1204. [PubMed PMID: 9351622. Epub 1997/11/14. eng].
5. Balough K., McCubbin M., Weinberger M., Smits W., Ahrens R., Fick R. The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr Pulmonol Aug 1995, 20(2):63-70. [PubMed PMID: 8570304. Epub 1995/08/01. eng].
6. Konstan M.W., Byard P.J., Hoppel C.L., Davis P.B. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med Mar 30 1995, 332(13):848-854. [PubMed PMID: 7503838. Epub 1995/03/30. eng].
7. Auerbach H.S., Williams M., Kirkpatrick J.A., Colten H.R. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet Sep 28 1985, 2(8457):686-688. [PubMed PMID: 2863676. Epub 1985/09/28. eng].
8. Konstan M.W., Schluchter M.D., Xue W., Davis P.B. Clinical use of ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J Respir Crit Care Med Dec 1 2007, 176(11):1084-1089. [PubMed PMID: 17872492. Pubmed Central PMCID: 2176097].
9. Eigen H., Rosenstein B.J., FitzSimmons S., Schidlow D.V. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group. J Pediatr Apr 1995, 126(4):515-523. [PubMed PMID: 7699528. Epub 1995/04/01. eng].
10. Sies H. Glutathione and its role in cellular functions. Free Radic Biol Med Nov 1999, 27(9-10):916-921. [PubMed PMID: 10569624. Epub 1999/11/24. eng].
11. Tirouvanziam R., Conrad C.K., Bottiglieri T., Herzenberg L.A., Moss R.B., Herzenberg L.A. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci U S A Mar 21 2006, 103(12):4628-4633. [PubMed PMID: 16537378. Pubmed Central PMCID: 1450222. Epub 2006/03/16. eng].
12. Lands L.C., Grey V., Smountas A.A., Kramer V.G., McKenna D. Lymphocyte glutathione levels in children with cystic fibrosis. Chest Jul 1999, 116(1):201-205. [PubMed PMID: 10424526. Epub 1999/07/29. eng].
13. Tirouvanziam R., Khazaal I., Peault B. Primary inflammation in human cystic fibrosis small airways. Am J Physiol Lung Cell Mol Physiol Aug 2002, 283(2):L445-L451. [PubMed PMID: 12114207. Epub 2002/07/13. eng].
14. Conrad C. Phase 2 trial of high-dose oral N-acetylcysteine as a systemic antioxidant and inhibitor of lung inflammation in CF. Pediatr Pulmonol 2006, 41(s29).
15. Mayer-Hamblett N., Aitken M.L., Accurso F.J., Kronmal R.A., Konstan M.W., Burns J.L., et al. Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am J Respir Crit Care Med Apr 15 2007, 75(8):822-828. [PubMed PMID: 17234902. Pubmed Central PMCID: 2720115. Epub 2007/01/20. eng].
16. Palmer L.A., Doctor A., Chhabra P., Sheram M.L., Laubach V.E., Karlinsey M.Z., et al. S-nitrosothiols signal hypoxia-mimetic vascular pathology. J Clin Invest Sep 2007, 117(9):2592-2601. [PubMed PMID: 17786245. Pubmed Central PMCID: 1952618. Epub 2007/09/06. eng].
17. Goss C.H., Edwards T.C., Ramsey B.W., Aitken M.L., Patrick D.L. Patient-reported respiratory symptoms in cystic fibrosis. J Cyst Fibros Jul 2009, 8(4):245-252. [PubMed PMID: 19481983. Epub 2009/06/02. eng].
18. Quittner A.L., Buu A., Messer M.A., Modi A.C., Watrous M. Development and validation of The Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest Oct 2005, 128(4):2347-2354. [PubMed PMID: 16236893. Epub 2005/10/21. eng].
19. Kerem E., Wilschanski M., Sernet-Gaudelus K., Be Boeach K., Accurso E.F., Konstan M. Ataluren CF Study Group. Interim results of the phase 3 open-label study of ataluren in nonsense mutation cystic fibrosis (nmCF). J Cyst Fibros 2013, 12(Suppl. 1).
20. Konstan M.W., Wagener J.S., Yegin A., Millar S.J., Pasta D.J., VanDevanter D.R. Design and powering of cystic fibrosis clinical trials using rate of FEV(1) decline as an efficacy endpoint. J Cyst Fibros Sep 2010, 9(5):332-338. [PubMed PMID: 20646968. Epub 2010/07/22. eng].
21. Hankinson J.L., Odencrantz J.R., Fedan K.B. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999 Jan, 159(1):179-187. [PubMed PMID: 9872837. Epub 1999/01/05. eng].
22. Wang X., Dockery D.W., Wypij D., Fay M.E., Ferris B.G. Pulmonary function between 6 and 18years of age. Pediatr Pulmonol Feb 1993, 15(2):75-88. [PubMed PMID: 8474788. Epub 1993/02/01. eng].
23. Standardization of Spirometry American Thoracic Society Am J Respir Crit Care Med Sep 1995, 152(3):1107-1136. 1994 Update, [PubMed PMID: 7663792. Epub 1995/09/01. eng].
24. Ramsey B.W., Dorkin H.L., Eisenberg J.D., Gibson R.L., Harwood I.R., Kravitz R.M., et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med Jun 17 1993, 328(24):1740-1746. [PubMed PMID: 8497284. Epub 1993/06/17. eng].
25. Sagel S.D., Kapsner R., Osberg I., Sontag M.K., Accurso F.J. Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction. Am J Respir Crit Care Med Oct 15 2001, 164(8 Pt 1):1425-1431. [PubMed PMID: 11704590. Epub 2001/11/13. eng].
26. Sagel S.D., Sontag M.K., Wagener J.S., Kapsner R.K., Osberg I., Accurso F.J. Induced sputum inflammatory measures correlate with lung function in children with cystic fibrosis. J Pediatr Dec 2002, 141(6):811-817. [PubMed PMID: 12461498. Epub 2002/12/04. eng].
27. Dauletbaev N., Fischer P., Aulbach B., Gross J., Kusche W., Thyroff-Friesinger U., et al. A phase II study on safety and efficacy of high-dose N-acetylcysteine in patients with cystic fibrosis. Eur J Med Res Aug 12 2009, 14(8):352-358. [PubMed PMID: 19666395. Pubmed Central PMCID: 3352166].
28. Chmiel J., Konstan M.W., Lymp J., Mayer-Hamblett N., Hilliard K.A., Accurso F.J., et al. Assessment of induced sputum as a tool to evaluate anti-inflammatory agents in CF. Pediatr Pulmonol 2007, 42(S30):228.
29. Griese M., Kappler M., Eismann C., Ballmann M., Junge S., Rietschel E., et al. Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized clinical trial. Am J Respir Crit Care Med Jul 1 2013, 188(1):83-89. [PubMed PMID: 23631796].
30. Zhang F., Lau S.S., Monks T.J. The cytoprotective effect of N-acetyl-L-cysteine against ROS-induced cytotoxicity is independent of its ability to enhance glutathione synthesis. Toxicol Sci Mar 2011, 120(1):87-97. [PubMed PMID: 21135414. Pubmed Central PMCID: 3044202. Epub 2010/12/08. eng].
31. Haddad J.J., Saade N.E., Safieh-Garabedian B. Redox regulation of TNF-alpha biosynthesis: augmentation by irreversible inhibition of gamma-glutamylcysteine synthetase and the involvement of an IkappaB-alpha/NF-kappaB-independent pathway in alveolar epithelial cells. Cell Signal Mar 2002, 14(3):211-218. [PubMed PMID: 11812649. Epub 2002/01/29. eng].
32. Li S., Yang X., Li W., Li J., Su X., Chen L., et al. N-acetylcysteine downregulation of lysyl oxidase activity alleviating bleomycin-induced pulmonary fibrosis in rats. Respiration Sep 20 2012, 84(6):509-517. [PubMed PMID: 23006535. Epub 2012/09/26. Eng].
33. Varelogianni G., Oliynyk I., Roomans G.M., Johannesson M. The effect of N-acetylcysteine on chloride efflux from airway epithelial cells. Cell Biol Int Mar 2010, 34(3):245-252. [PubMed PMID: 19947928].
34. Fu L., Sztul E. ER-associated complexes (ERACs) containing aggregated cystic fibrosis transmembrane conductance regulator (CFTR) are degraded by autophagy. Eur J Cell Biol Apr 2009, 88(4):215-226. [PubMed PMID: 19131141. Pubmed Central PMCID: 2696269].
35. Luciani A., Villella V.R., Esposito S., Brunetti-Pierri N., Medina D., Settembre C., et al. Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition. Nat Cell Biol Sep 2010, 12(9):863-875. [PubMed PMID: 20711182].
36. 2 and inflammatory cytokine production. PLoS One 2008, 3(10):e3367. [PubMed PMID: 18846238. Pubmed Central PMCID: 2563038].